Shanghai Medicilon Inc (688202) - Total Assets
Based on the latest financial reports, Shanghai Medicilon Inc (688202) holds total assets worth CN¥2.83 Billion CNY (≈ $414.70 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 688202 net assets for net asset value and shareholders' equity analysis.
Shanghai Medicilon Inc - Total Assets Trend (2016–2024)
This chart illustrates how Shanghai Medicilon Inc's total assets have evolved over time, based on quarterly financial data.
Shanghai Medicilon Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Shanghai Medicilon Inc's total assets of CN¥2.83 Billion consist of 50.9% current assets and 49.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 9.2% |
| Accounts Receivable | CN¥548.14 Million | 19.4% |
| Inventory | CN¥104.36 Million | 3.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥278.15 Million | 9.9% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Shanghai Medicilon Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Shanghai Medicilon Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Medicilon Inc's current assets represent 50.9% of total assets in 2024, a decrease from 69.9% in 2016.
- Cash Position: Cash and equivalents constituted 9.2% of total assets in 2024, down from 41.8% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 19.4% of total assets.
Shanghai Medicilon Inc Competitors by Total Assets
Key competitors of Shanghai Medicilon Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥7.26 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥38.02 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $504.60 Million |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $563.83 Million |
Shanghai Medicilon Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.70 | 3.16 | 4.18 |
| Quick Ratio | 2.56 | 2.87 | 4.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥912.64 Million | CN¥1.06 Billion | CN¥467.37 Million |
Shanghai Medicilon Inc - Advanced Valuation Insights
This section examines the relationship between Shanghai Medicilon Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.33 |
| Latest Market Cap to Assets Ratio | 0.43 |
| Asset Growth Rate (YoY) | -13.6% |
| Total Assets | CN¥2.82 Billion |
| Market Capitalization | $1.22 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Medicilon Inc's assets below their book value (0.43x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shanghai Medicilon Inc's assets decreased by 13.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shanghai Medicilon Inc (2016–2024)
The table below shows the annual total assets of Shanghai Medicilon Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.82 Billion ≈ $413.13 Million |
-13.55% |
| 2023-12-31 | CN¥3.27 Billion ≈ $477.90 Million |
+40.19% |
| 2022-12-31 | CN¥2.33 Billion ≈ $340.89 Million |
+29.89% |
| 2021-12-31 | CN¥1.79 Billion ≈ $262.46 Million |
+31.46% |
| 2020-12-31 | CN¥1.36 Billion ≈ $199.64 Million |
+20.92% |
| 2019-12-31 | CN¥1.13 Billion ≈ $165.11 Million |
+138.57% |
| 2018-12-31 | CN¥472.95 Million ≈ $69.21 Million |
+21.39% |
| 2017-12-31 | CN¥389.61 Million ≈ $57.01 Million |
+12.96% |
| 2016-12-31 | CN¥344.90 Million ≈ $50.47 Million |
-- |
About Shanghai Medicilon Inc
Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers medicinal and analytical chemistry; process development; custom and zoom in synthesis; structural, in … Read more